제약 바이오 뉴스

<div> <img width="723" height="52" class="txc-image" id="tx_entry_51972_" style="width: 691px; height: 53px; clear: none; float: none;" src="https://t1.daumcdn.net/cfile/cafe/251C134D58803B7716" border="0" vspace="1" hspace="1" data-filename="상단.jpg" exif="{}" actualwidth="887" id="A_251C134D58803B77168C10"/> 대웅제약, '혁신신약' 심장 섬유증 치료제 효능 입증<span style='color: rgb(9, 0, 255); font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-font-family: "맑은 고딕"; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Malgun Gothic";'>… 美 <span style='color: rgb(9, 0, 255); font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-font-family: "맑은 고딕"; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "맑은 고딕";'>심장학회서 발표 <span style='color: rgb(9, 0, 255); font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-font-family: "맑은 고딕"; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;'>(조선비즈)   - 대웅제약이 심장섬유증 치료제로 개발하고 있는 PRS(Prolyl-tRNA Synthetase) 저해제인<span style='font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-font-family: "맑은 고딕"; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Malgun Gothic";'>‘DWN12088<span style='font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-font-family: "맑은 고딕"; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Malgun Gothic";'>’의 전임상 결과 심근경색 후 PRS 단백질 활성만을 선택적으로 감소시켜 섬유화를 강력하게 억제 -심장섬유화와 과도한 염증 현상을 근본적으로 치료할 수 있는 경구용(먹는) 심장섬유증 치료 물질 한미약품 "고혈압<span style='font-family: "맑은 고딕"; font-size: 11pt; mso-ascii-theme-font: minor-fareast; mso-fareast-font-family: "맑은 고딕"; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Malgun Gothic";'>·고지혈증 복합제' 아모잘탄큐', 임상3상서 강력한 강압 효과 입증" (조선비즈) -아모잘탄큐는 한미약품이 자체 개발한 세계 첫 고혈압<span style='font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-font-family: "맑은 고딕"; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Malgun Gothic";'>·고지혈증 3제(3가지성분을하나로결합) 복합제로 지난10월 출시 <span style='color: black; font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "KoPubDotum Light"; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA;'>-<span style='color: black; font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "KoPubDotum Light"; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA;'>아모잘탄큐의 경우 기존의 고혈압<span style='color: black; font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Malgun Gothic"; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA;'>·<span style='color: black; font-family: "맑은 고딕"; font-size: 12pt; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "KoPubDotum Light"; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA;'>스타틴 복합제와 비교할때 한 알의 편리함은 유지하면서도 보다 강력한 혈압 조절 효과를 기대 <img width="695" height="36" class="txc-image" id="tx_entry_12754_" style="width: 695px; height: 36px; clear: none; float: none;" src="https://t1.daumcdn.net/cfile/cafe/255D754858803B9E22" border="0" vspace="1" hspace="1" data-filename="하단.jpg" exif="{}" actualwidth="853" id="A_255D754858803B9E22DC87"/> </div>